Biocytogen Prescription drugs (Beijing) Co., Ltd. (“Biocytogen”) right now introduced the launch of the “Nano 100 Venture”, which goals to develop absolutely human nanobody medicine for over 100 targets. The Venture combines Biocytogen’s proprietary absolutely human nanobody mouse, RenNanoTM, with its high-throughput in vitro and in vivo antibody screening platforms to develop absolutely human nanobody medicine on a large-scale.
In comparison with conventional antibodies, nanobodies have smaller molecular weights and improved tissue penetration means, which make them efficient at infiltrating tumors and crossing blood-brain boundaries. Moreover, nanobodies usually have longer CDR3 areas which permits them to acknowledge hidden epitopes higher. Resulting from their easier construction, nanobodies are extra secure and simpler to provide and engineer, making them excellent constructing blocks for complicated modalities resembling cell remedy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC).
After a number of years of endeavor, Biocytogen efficiently engineered the RenNano mouse from its absolutely human antibody mouse, RenMabTM. RenNano mouse possesses full human heavy chain variable areas and might produce heavy-chain-only antibodies (HCAbs). The variable areas of HCAbs, i.e., nanobodies, don’t require in vitro humanization to develop medicine. Our analysis has proven that RenNano mouse can generate strong immune responses after immunizations by totally different antigens. HCAbs generated from the RenNano mouse have extremely numerous CDR3 sequences and might acknowledge many epitopes with nM-level excessive affinities. In vitro and in vivo experiments have proven that RenNano-derived antibodies have favorable organic capabilities.
Primarily based on RenNano’s wonderful means to find absolutely human nanobodies, Biocytogen has launched the “Nano 100 Venture”. The Venture goals to develop absolutely human therapeutic nanobodies towards over 100 targets, together with tumor related antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and components associated to neurological ailments. Biocytogen is actively in search of collaborations with world pharmaceutical and biotech firms to mix its large-scale nanobody improvement skills with collaborators’ experience in nanobody-related therapeutics, resembling cell therapies, bispecific and multi-specific antibodies, ADCs and RACs, to develop novel medicine with first-in-class and/or best-in-class potentials.
“We consider that with the flexibility to quickly develop absolutely human nanobodies towards chosen targets, the ‘Nano 100 Venture’ will present our world companions with extra numerous and higher nanobody constructing blocks to speed up the event of novel medicine,” mentioned Dr. Yuelei Shen, President and CEO of Biocytogen. “In the meantime, additionally it is an vital complement to Biocytogen’s Venture Integrum.”
Supply: https://en.biocytogen.com.cn/
